Sorrento Therapeutics ( ) - 株価, ニュースと分析OTCPK:SRNE.Q

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

SRNE.Q 株式概要

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.

会社概要

SRNE.Q fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

報酬

リスク分析

過去3か月間の株価の変動は非常に激しい

過去5年間で収益は年間27.1%減少しました。

マイナスの株主資本

キャッシュランウェイが1年未満である

+2 さらなるリスク

Sorrento Therapeutics, Inc. 競合他社

Atara Biotherapeutics

NasdaqGS:ATRA

US$61.5m

Dyadic International

NasdaqCM:DYAI

US$60.8m

Cidara Therapeutics

NasdaqCM:CDTX

US$61.3m

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$50.0m

価格と性能

Summary of all time highs, changes and price drops for Sorrento Therapeutics
Historical stock prices
Current Share Price	US$0.11
52 Week High	US$1.23
52 Week Low	US$0.021
Beta	2.1
1 Month Change	159.95%
3 Month Change	13.27%
1 Year Change	-90.59%
3 Year Change	-98.50%
5 Year Change	-95.49%
Change since IPO	-99.11%

Recent updates

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sep 29

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sep 15

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug 31

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Aug 23

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Aug 17

株主還元

	SRNE.Q	US Biotechs	US 市場
7D	-5.5%	-2.0%	1.6%
1Y	-90.6%	5.4%	21.5%

業界別リターン: SRNE.Q過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: SRNE.Qは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is SRNE.Q's price volatile compared to industry and market?
SRNE.Q volatility
SRNE.Q Average Weekly Movement	106.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

安定した株価: SRNE.Qの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: SRNE.Qの週次ボラティリティは、過去 1 年間で57%から106%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2006	949	Henry Ji	www.sorrentotherapeutics.com

Sorrento Therapeutics, Inc. 基礎のまとめ

Sorrento Therapeutics の収益と売上を時価総額と比較するとどうか。
SRNE.Q 基礎統計学
時価総額	US$60.35m
収益（TTM）	-US$548.00m
売上高(TTM)	US$64.27m

0.9x

P/Sレシオ

-0.1x

PER（株価収益率

SRNE.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
SRNE.Q 損益計算書（TTM）
収益	US$64.27m
売上原価	US$221.74m
売上総利益	-US$157.47m
その他の費用	US$390.53m
収益	-US$548.00m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.01
グロス・マージン	-245.01%
純利益率	-852.65%
有利子負債／自己資本比率	-71.8%

SRNE.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

SRNE.Q 株式概要

報酬

リスク分析

Sorrento Therapeutics, Inc. 競合他社

NasdaqGS:ATRA

US$61.5m

NasdaqCM:DYAI

US$60.8m

NasdaqCM:CDTX

US$61.3m

NasdaqGM:EGRX

US$50.0m

価格と性能

最新ニュース

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

No longer forecast to breakeven

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.00

No longer forecast to breakeven

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics: The Enigma

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors